Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 129

1.

Avoiding chemotherapy prescribing errors: Analysis and innovative strategies.

Reinhardt H, Otte P, Eggleton AG, Ruch M, Wöhrl S, Ajayi S, Duyster J, Jung M, Hug MJ, Engelhardt M.

Cancer. 2019 Jan 29. doi: 10.1002/cncr.31950. [Epub ahead of print]

PMID:
30695105
2.

Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation.

Zeiser R, Beelen DW, Bethge W, Bornhäuser M, Bug G, Burchert A, Christopeit M, Duyster J, Finke J, Gerbitz A, Klusmann JH, Kobbe G, Lübbert M, Müller-Tidow C, Platzbecker U, Rösler W, Sauer M, Schmid C, Schroeder T, Stelljes M, Kröger N, Müller LP.

Biol Blood Marrow Transplant. 2019 Jan 15. pii: S1083-8791(19)30065-5. doi: 10.1016/j.bbmt.2019.01.016. [Epub ahead of print] Review.

PMID:
30658222
3.

Droplet digital PCR for the simultaneous analysis of minimal residual disease and hematopoietic chimerism after allogeneic cell transplantation.

Waterhouse M, Pfeifer D, Duque-Afonso J, Follo M, Duyster J, Depner M, Bertz H, Finke J.

Clin Chem Lab Med. 2018 Nov 20. pii: /j/cclm.ahead-of-print/cclm-2018-0827/cclm-2018-0827.xml. doi: 10.1515/cclm-2018-0827. [Epub ahead of print]

PMID:
30457973
4.
5.

APC/CCdh1 regulates the balance between maintenance and differentiation of hematopoietic stem and progenitor cells.

Ewerth D, Kreutmair S, Schmidts A, Ihorst G, Follo M, Wider D, Felthaus J, Schüler J, Duyster J, Illert AL, Engelhardt M, Wäsch R.

Cell Mol Life Sci. 2019 Jan;76(2):369-380. doi: 10.1007/s00018-018-2952-3. Epub 2018 Oct 24.

PMID:
30357422
6.

CBP Modulates Sensitivity to Dasatinib in Pre-BCR+ Acute Lymphoblastic Leukemia.

Duque-Afonso J, Lin CH, Han K, Morgens DW, Jeng EE, Weng Z, Jeong J, Wong SHK, Zhu L, Wei MC, Chae HD, Schrappe M, Cario G, Duyster J, Xiao X, Sakamoto KM, Bassik MC, Cleary ML.

Cancer Res. 2018 Nov 15;78(22):6497-6508. doi: 10.1158/0008-5472.CAN-18-1703. Epub 2018 Sep 27.

PMID:
30262461
7.

Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life.

Greil C, Engelhardt M, Ihorst G, Schoeller K, Bertz H, Marks R, Zeiser R, Duyster J, Einsele H, Finke J, Wäsch R.

Haematologica. 2019 Feb;104(2):370-379. doi: 10.3324/haematol.2018.200881. Epub 2018 Sep 20.

8.

Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas.

Poggio T, Duyster J, Illert AL.

Cancers (Basel). 2018 Sep 18;10(9). pii: E339. doi: 10.3390/cancers10090339. Review.

9.

Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation.

Sommer S, Cruijsen M, Claus R, Bertz H, Wäsch R, Marks R, Zeiser R, Bogatyreva L, Blijlevens NMA, May A, Duyster J, Huls G, van der Velden WJFM, Finke J, Lübbert M.

Leuk Res. 2018 Sep;72:20-26. doi: 10.1016/j.leukres.2018.07.005. Epub 2018 Jul 7.

PMID:
30064039
10.

Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatment.

Stosch JM, Heumüller A, Niemöller C, Bleul S, Rothenberg-Thurley M, Riba J, Renz N, Szarc Vel Szic K, Pfeifer D, Follo M, Pahl HL, Zimmermann S, Duyster J, Wehrle J, Lübbert M, Metzeler KH, Claus R, Becker H.

Br J Haematol. 2018 Sep;182(6):830-842. doi: 10.1111/bjh.15461. Epub 2018 Jul 5.

PMID:
29974943
11.

Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma).

Waldschmidt JM, Keller A, Ihorst G, Grishina O, Müller S, Wider D, Frey AV, King K, Simon R, May A, Tassone P, Duyster J, Jung M, Raje N, Wäsch R, Engelhardt M.

Haematologica. 2018 Oct;103(10):e473-e479. doi: 10.3324/haematol.2018.189969. Epub 2018 Apr 19. No abstract available.

12.

Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Apr 10;24(4):526. doi: 10.1038/nm0418-526c.

PMID:
29634689
13.

Navigating the changing multiple myeloma treatment landscape: clinical practice patterns of MM patients treated in- and outside German DSMM study group trials.

Gengenbach L, Reinhardt H, Ihorst G, Ajayi S, Dold SM, Köhler M, Einsele H, Duyster J, Wäsch R, Engelhardt M.

Leuk Lymphoma. 2018 Nov;59(11):2692-2699. doi: 10.1080/10428194.2018.1448084. Epub 2018 Mar 23. No abstract available.

PMID:
29569975
14.

Anti-Angiogenics: Current Situation and Future Perspectives.

Zirlik K, Duyster J.

Oncol Res Treat. 2018;41(4):166-171. doi: 10.1159/000488087. Epub 2018 Mar 23.

15.

Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms.

Prestipino A, Emhardt AJ, Aumann K, O'Sullivan D, Gorantla SP, Duquesne S, Melchinger W, Braun L, Vuckovic S, Boerries M, Busch H, Halbach S, Pennisi S, Poggio T, Apostolova P, Veratti P, Hettich M, Niedermann G, Bartholomä M, Shoumariyeh K, Jutzi JS, Wehrle J, Dierks C, Becker H, Schmitt-Graeff A, Follo M, Pfeifer D, Rohr J, Fuchs S, Ehl S, Hartl FA, Minguet S, Miething C, Heidel FH, Kröger N, Triviai I, Brummer T, Finke J, Illert AL, Ruggiero E, Bonini C, Duyster J, Pahl HL, Lane SW, Hill GR, Blazar BR, von Bubnoff N, Pearce EL, Zeiser R.

Sci Transl Med. 2018 Feb 21;10(429). pii: eaam7729. doi: 10.1126/scitranslmed.aam7729.

PMID:
29467301
16.

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Mar;24(3):282-291. doi: 10.1038/nm.4484. Epub 2018 Feb 12. Erratum in: Nat Med. 2018 Apr 10;24(4):526.

PMID:
29431743
17.

Cell-free DNA characteristics and chimerism analysis in patients after allogeneic cell transplantation.

Duque-Afonso J, Waterhouse M, Pfeifer D, Follo M, Duyster J, Bertz H, Finke J.

Clin Biochem. 2018 Feb;52:137-141. doi: 10.1016/j.clinbiochem.2017.11.015. Epub 2017 Nov 24.

PMID:
29180242
18.

Microenvironmental stromal cells abrogate NF-κB inhibitor-induced apoptosis in chronic lymphocytic leukemia.

Simon-Gabriel CP, Foerster K, Saleem S, Bleckmann D, Benkisser-Petersen M, Thornton N, Umezawa K, Decker S, Burger M, Veelken H, Claus R, Dierks C, Duyster J, Zirlik K.

Haematologica. 2018 Jan;103(1):136-147. doi: 10.3324/haematol.2017.165381. Epub 2017 Nov 9.

19.

Stem cell mobilization in poor mobilizers with multiple myeloma or lymphoma before and after introduction of plerixafor: a single-center comparative analysis using a cost-efficient single fixed-dose schedule.

Greil C, Ihorst G, Kiote-Schmidt C, Hildenbeutel S, Kühbach K, Bosse R, Duyster J, Engelhardt M, Wäsch R.

Leuk Lymphoma. 2018 Jul;59(7):1722-1725. doi: 10.1080/10428194.2017.1393673. Epub 2017 Oct 30. No abstract available.

PMID:
29081261
20.

The oligodendrocyte lineage transcription factor 2 (OLIG2) is epigenetically regulated in acute myeloid leukemia.

Yalcin A, Kovarbasic M, Wehrle J, Claus R, Becker H, Abdelkarim M, Gaidzik VI, Schmidts A, Wäsch R, Pahl HL, Döhner K, Bullinger L, Duyster J, Lübbert M, Hackanson B.

Exp Hematol. 2017 Nov;55:76-85.e3. doi: 10.1016/j.exphem.2017.07.009. Epub 2017 Jul 28.

PMID:
28760688

Supplemental Content

Loading ...
Support Center